<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671697</url>
  </required_header>
  <id_info>
    <org_study_id>07-0916 / 201011797</org_study_id>
    <nct_id>NCT00671697</nct_id>
  </id_info>
  <brief_title>Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic&#xD;
      acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes (MDS) are hematological disorders characterized by ineffective&#xD;
      hematopoiesis. DNA hypomethylating agents such as decitabine have been shown to have activity&#xD;
      in this disorder by reversing the epigenetic mechanism of gene silencing.&#xD;
&#xD;
      Acute Myeloid Leukemia (AML) is a hematological disorder characterized by ineffective&#xD;
      hematopoiesis and malignant expansion of clonal myeloid cells. In elderly patients (≥ 60&#xD;
      years old), MDS commonly precedes the diagnosis of AML. Standard therapy for AML consists of&#xD;
      cytotoxic chemotherapy and is often followed with allogeneic stem cell transplantation.&#xD;
      Unfortunately, elderly patients are often unable to tolerate such aggressive therapy.&#xD;
&#xD;
      Arsenic has also shown activity in patients with MDS and AML though modulation of apoptosis&#xD;
      via increased oxidative stress. In preclinical modes, arsenic activity is related to the&#xD;
      production of radical oxygen species that damage mitochondria. Cellular glutathione acts as a&#xD;
      cellular antioxidant and can be depleted with the vitamin ascorbic acid which increases&#xD;
      intracellular oxidative stress and sensitivity to arsenic trioxide induced apoptosis.&#xD;
&#xD;
      We are studying the combination of decitabine, arsenic trioxide and ascorbic acid, two&#xD;
      primary agents and one vitamin all with different mechanisms of action in order to improve&#xD;
      the response rate in patients with MDS and AML. This is an open-label, single-arm,&#xD;
      single-center, dose escalation Phase I trial of decitabine, arsenic trioxide and ascorbic&#xD;
      acid in patients with MDS, either de novo or secondary, fitting any of the FAB&#xD;
      classifications and AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the maximum tolerated dose and dose-limiting toxicities during four cycles of combination decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) previously untreated with hypomethylating agents.</measure>
    <time_frame>4 months after the final patient on the final cohort starts treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the rate of complete remission (CR) and partial remission (PR) after four cycles of therapy in patients with MDS.</measure>
    <time_frame>After 4 cycles of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of hematologic improvement</measure>
    <time_frame>Weekly through the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of transfusion independence</measure>
    <time_frame>Through completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to disease progression to AML</measure>
    <time_frame>Every 4 weeks during treatment and then every 2 months for 2 years after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of cytogenetic response</measure>
    <time_frame>After every 2 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the rate of overall survival</measure>
    <time_frame>Every 4 weeks during treatment and then every 2 months for 2 years after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine changes in bone marrow vascular density</measure>
    <time_frame>At baseline, end of cycle 2, end of cycle 4, and end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine changes in angiogenic mRNA expression.</measure>
    <time_frame>Baseline, end of cycle 2, end of cycle 4, and end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Myelodysplastic Syndromes and Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.&#xD;
Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.&#xD;
Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.&#xD;
Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <arm_group_label>Dose Level 1 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_label>Dose Level 2 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_label>Dose Level 3 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <other_name>Dacogen, Vitamin C and Trisenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <arm_group_label>Dose Level 1 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_label>Dose Level 2 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <arm_group_label>Dose Level 3 Arsenic Trioxide &amp; Decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. MDS (either de novo or secondary) fitting any of the FAB classifications or AML&#xD;
             defined by FAB classification criteria. Patients with &lt; 5% bone marrow blasts must&#xD;
             also meet one of the following criteria:&#xD;
&#xD;
               1. Symptomatic anemia with either hemoglobin &lt;10.0 g/dL or requiring red blood cell&#xD;
                  (RBC) transfusion&#xD;
&#xD;
               2. Thrombocytopenia with a history of two or more platelet counts &lt; 50,000 / µL or a&#xD;
                  significant hemorrhage requiring platelet transfusions, or&#xD;
&#xD;
               3. Neutropenia with two or more absolute neutrophil counts &lt; 1,000 /µL.&#xD;
&#xD;
             AML patients must also have a WBC &lt; 10,000µL and meet one of the following two&#xD;
             criteria:&#xD;
&#xD;
               1. Age greater than or equal to 60 years&#xD;
&#xD;
               2. Relapsed AML and are not a candidate for cytotoxic chemotherapy.&#xD;
&#xD;
          2. ECOG performance status of 0-2.&#xD;
&#xD;
          3. Must give written informed consent indicating their awareness of the investigational&#xD;
             nature of this study and its potential hazards.&#xD;
&#xD;
          4. Adequate renal and hepatic function (creatinine &lt; 1.5x institutional upper limit of&#xD;
             normal, total bilirubin ≤ 1.5x institutional upper limit of normal, AST and ALT ≤ 2x&#xD;
             institutional upper limit of normal).&#xD;
&#xD;
          5. Serum potassium &gt; 4.0 mEq/L, serum magnesium &gt; 1.8 mg/dL.&#xD;
&#xD;
          6. Life expectancy of at least 16 weeks.&#xD;
&#xD;
          7. Women of childbearing age must have a negative serum pregnancy test prior to&#xD;
             initiating therapy.&#xD;
&#xD;
          8. Sexually active women of childbearing potential must use effective birth control&#xD;
             during the trial and for at least two months following the trial.&#xD;
&#xD;
          9. Men must be willing to avoid fathering a new child while receiving therapy with&#xD;
             decitabine.&#xD;
&#xD;
         10. Greater than or equal to 18 years, no upper age limit&#xD;
&#xD;
         11. Individuals who are candidates for hematopoietic stem cell transplantation and who&#xD;
             meet all other study criteria may participate in the study and receive intravenous&#xD;
             decitabine in combination with arsenic trioxide and Ascorbic acid as a treatment prior&#xD;
             to transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known central nervous system (CNS) leukemia.&#xD;
&#xD;
          2. Previously received greater than or equal to 5 cycles of azacitidine (Vidaza®,&#xD;
             Pharmion Corp., Boulder, CO) or decitabine (Dacogen®, MGI Pharma Inc. Bloomington,&#xD;
             MN).&#xD;
&#xD;
          3. QTc &gt; 460 msec.&#xD;
&#xD;
          4. Known or suspected hypersensitivity to decitabine, arsenic or ascorbic acid.&#xD;
&#xD;
          5. Receiving any other investigational agents within 30 days of first dose of study drug.&#xD;
&#xD;
          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, congestive heart failure of NYHA class 3 or 4, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situation that would limit&#xD;
             compliance with study requirements.&#xD;
&#xD;
          7. Known positive serology for HIV.&#xD;
&#xD;
          8. Had radiotherapy within 14 days prior to study enrollment.&#xD;
&#xD;
          9. Known presence of hepatic tumors.&#xD;
&#xD;
         10. &lt; 18 years of age&#xD;
&#xD;
         11. Exclude women who are pregnant or breast feeding.&#xD;
&#xD;
         12. Known history of glucose-6-phosphate deficiency (G6PD).&#xD;
&#xD;
         13. Currently taking a Class Ia or Class III antiarrhythmic or other medication causally&#xD;
             associated with prolonging QTc.&#xD;
&#xD;
         14. Use of aspirin with platelet counts &lt; 50,000/µl.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Vij, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univerisity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>hypomethylating agent</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

